MX2017002986A - Compuestos de piperidina sustituidos. - Google Patents

Compuestos de piperidina sustituidos.

Info

Publication number
MX2017002986A
MX2017002986A MX2017002986A MX2017002986A MX2017002986A MX 2017002986 A MX2017002986 A MX 2017002986A MX 2017002986 A MX2017002986 A MX 2017002986A MX 2017002986 A MX2017002986 A MX 2017002986A MX 2017002986 A MX2017002986 A MX 2017002986A
Authority
MX
Mexico
Prior art keywords
compounds
substituted piperidine
present disclosure
piperidine compounds
formula
Prior art date
Application number
MX2017002986A
Other languages
English (en)
Inventor
John Munchhof Michael
Chesworth Richard
Helen Mitchell Lorna
Simon Bell Andrew
Wayne KUNTS Kevin
Edward John Mills James
Alene Cloonan FOLEY Megan
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MX2017002986A publication Critical patent/MX2017002986A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción proporciona compuestos de piperidina sustituidos que tienen la Formula I: (ver formula I) y las sales y solvatos farmacéuticamente aceptables de los mismos, en donde R1, B, X y Z se definen como se recoge en la memoria descriptiva. La presente descripción también se dirige al use de compuestos de Formula I para tratar un trastorno que responde al bloqueo de proteínas SMYD tales como SMYD3 o SMYD2. Compuestos de la presente descripción son especialmente Útiles para tratar el cáncer.
MX2017002986A 2014-09-10 2015-09-09 Compuestos de piperidina sustituidos. MX2017002986A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462048771P 2014-09-10 2014-09-10
US201462078845P 2014-11-12 2014-11-12
US201562146790P 2015-04-13 2015-04-13
PCT/US2015/049235 WO2016040515A1 (en) 2014-09-10 2015-09-09 Substituted piperidine compounds

Publications (1)

Publication Number Publication Date
MX2017002986A true MX2017002986A (es) 2017-10-24

Family

ID=55459535

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002986A MX2017002986A (es) 2014-09-10 2015-09-09 Compuestos de piperidina sustituidos.

Country Status (13)

Country Link
US (1) US10577363B2 (es)
EP (1) EP3193605A4 (es)
JP (1) JP2017528464A (es)
KR (1) KR20170047397A (es)
CN (1) CN107072207A (es)
AU (1) AU2015315182A1 (es)
BR (1) BR112017004589A2 (es)
CA (1) CA2960280A1 (es)
EA (1) EA201790327A1 (es)
IL (1) IL250888A0 (es)
MX (1) MX2017002986A (es)
SG (2) SG11201701597RA (es)
WO (1) WO2016040515A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266526B2 (en) 2014-09-10 2019-04-23 Epizyme, Inc. Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
EP3193606B1 (en) 2014-09-10 2020-06-24 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
EP3193603A4 (en) 2014-09-10 2018-02-28 Epizyme, Inc. Isoxazole carboxamide compounds
JP2017527576A (ja) 2014-09-10 2017-09-21 エピザイム，インコーポレイティド 置換シクロヘキシルアミン化合物
CA2977919A1 (en) * 2015-02-27 2016-09-01 Op Bio Factory Co., Ltd. Method for producing kakeromycin and derivatives thereof
PL3798217T3 (pl) * 2016-07-28 2023-06-12 Idorsia Pharmaceuticals Ltd Piperydynowe modulatory receptora cxcr7
WO2018151678A1 (en) * 2017-02-15 2018-08-23 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics
HUE066704T2 (hu) * 2018-01-26 2024-08-28 Idorsia Pharmaceuticals Ltd CXCR7 receptor antagonista (3S,4S)-1-ciklopropilmetil-4-{[5-(2,4-difluor-fenil)-izoxazol-3-karbonil]-amino} -piperidin-3-karbonsav-(1-pirimidin-2-il-ciklopropil)-amid kristályos formái
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
SG11202102440SA (en) 2018-10-29 2021-04-29 Boehringer Ingelheim Int Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
WO2021065898A1 (ja) 2019-09-30 2021-04-08 日本ケミファ株式会社 アゼパン誘導体
CN114702552B (zh) * 2022-03-11 2024-05-31 苏州思萃免疫技术研究所有限公司 mTORC2抑制剂
WO2024067708A1 (zh) * 2022-09-30 2024-04-04 苏州阿尔脉生物科技有限公司 草酸胺类衍生物、包含其的药物组合物及其医药用途
WO2025133989A1 (en) * 2023-12-20 2025-06-26 Alt-Bio Pte. Ltd. Smyd modulators and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228288B (it) * 1989-01-09 1991-06-07 Zambon Spa Composti ad attivita' antiserotoninica
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SE0403106D0 (sv) * 2004-12-20 2004-12-20 Astrazeneca Ab Chemical compounds
US20090062286A1 (en) * 2007-05-04 2009-03-05 Kenneth William Foreman Crystal Structure of SMYD3 Protein
WO2009072643A1 (en) * 2007-12-03 2009-06-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
JP5927201B2 (ja) * 2010-12-16 2016-06-01 カルチャン リミテッド Ａｓｋ１阻害ピロロピリミジン誘導体
EP3193606B1 (en) 2014-09-10 2020-06-24 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
EP3193603A4 (en) 2014-09-10 2018-02-28 Epizyme, Inc. Isoxazole carboxamide compounds
JP2017527576A (ja) 2014-09-10 2017-09-21 エピザイム，インコーポレイティド 置換シクロヘキシルアミン化合物
JP2017527577A (ja) 2014-09-10 2017-09-21 エピザイム，インコーポレイティド 置換ピロリジン化合物
US10266526B2 (en) 2014-09-10 2019-04-23 Epizyme, Inc. Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
CA2960277A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds

Also Published As

Publication number Publication date
WO2016040515A1 (en) 2016-03-17
KR20170047397A (ko) 2017-05-04
CN107072207A (zh) 2017-08-18
SG11201701597RA (en) 2017-03-30
EP3193605A1 (en) 2017-07-26
AU2015315182A1 (en) 2017-03-16
CA2960280A1 (en) 2016-03-17
EA201790327A1 (ru) 2017-10-31
SG10201901189SA (en) 2019-03-28
JP2017528464A (ja) 2017-09-28
EP3193605A4 (en) 2018-04-18
US10577363B2 (en) 2020-03-03
US20170362217A1 (en) 2017-12-21
IL250888A0 (en) 2017-04-30
BR112017004589A2 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
MX2023006257A (es) Inhibidores de smyd.
SG10201901189SA (en) Substituted piperidine compounds
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
MX384087B (es) Piperidinas como inhibidores de menina.
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
MX384905B (es) Degradadores de proteínas de bromodominio y dominioextraterminal (bet).
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2015013481A (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
NZ727185A (en) Phosphatidylinositol 3-kinase inhibitors
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
TW201613865A (en) Heteroaryls and uses thereof
MA40170A (fr) Dérivés hétérocycliques de morphinan et leur utilisation
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX390051B (es) Antagonistas de ep4.
MD20170011A2 (ro) Compuşi imidazopiridazinici
JOP20190163B1 (ar) منشط nrf2
IN2013MU03862A (es)
PH12014501712B1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
PH12017501214A1 (en) Cgrp antagonist peptides
HK1240469A1 (en) Substituted piperidine compounds
TN2014000307A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors